Novozymes Biopharma to present latest advances in drug delivery technology at Controlled Release Society Meeting

Novozymes will highlight the use of hyaluronic acid (HA) to extend drug release in osteoarthritis applications.

Novozymes Biopharma, part of Novozymes A/S, world leader in bioinnovation, today announced two new scientific posters to be presented at the 2011 Controlled Release Society (CRS) meeting and exposition, July 30–August 3, Maryland, USA.

Novozymes will highlight the use of hyaluronic acid (HA) to extend drug release in osteoarthritis applications.

The posters highlight the formulation and stabilization capabilities of recombinant albumin (rAlbumin) to safeguard the integrity of protein drug substances as well as the potential for combining hyaluronic acid (HA) and diclofenac sodium to extend drug release in osteoarthritis applications. For more information or to request a copy of the scientific posters, please visit booth #301 at the 2011 CRS meeting or www.biopharma.novozymes.com.

“Novozymes is delighted to present its latest study findings in the application of advanced drug delivery technology at the 2011 CRS meeting,” comments Dermot Pearson, Marketing Director at Novozymes Biopharma. “We are committed to developing compliant formulation solutions that ensure improved stability, solubility and half-life of biotherapeutics and we are delighted to demonstrate how these innovative products can streamline the drug development process.”

The first poster, entitled ‘Recombinant Albumin: A multipurpose excipient for formulation and stabilization of biotherapeutics’, examines rAlbumin as an effective stabilizing excipient for 3D7 and FC27 malaria antigen proteins in liquid formulations. The findings demonstrate the potential of rAlbumin to safeguard proteins’ integrity preventing aggregation, oxidation and non-specific binding.

The second poster is entitled ‘Compatibility between diclofenac sodium and hyaluronic acid and release of diclofenac sodium from hyaluronic acid-containing preparations towards the treatment of osteoarthritis’. The findings of the poster indicate that the addition of HA to diclofenac-containing commercial formulations can extend drug release from less than 15 minutes to 10 hours, offering new advances for future intra-articular preparations intended for the treatment of osteoarthritis.

For further information on Novozymes’ range of innovative drug delivery products or to request a copy of the scientific posters, please visit booth #301 at the 2011 CRS meeting or www.biopharma.novozymes.com.